The projected revenue growth for Galafold, a key product for Amicus Therapeutics, indicates a positive outlook for the company's financial health and market performance. Achieving non-GAAP profitability is a significant milestone that could enhance investor confidence and potentially lead to a positive impact on the stock price in the short term.